George J. Dugbartey
Abstract:Ischemia–reperfusion injury (IRI) is a critical pathological condition in which cell death plays a major contributory role, and negatively impacts post-transplant outcomes. At the cellular level, hypoxia due to ischemia disturbs cellular metabolism and decreases cellular bioenergetics through dysfunction of mitochondrial electron transport chain, causing a switch from cellular respiration to anaerobic metabolism, and subsequent cascades of events that lead to increased intracellular concentrations of Na + , H + and Ca 2+ and consequently cellular edema. Restoration of blood supply after ischemia provides oxygen to the ischemic tissue in excess of its requirement, resulting in over-production of reactive oxygen species (ROS), which overwhelms the cells' antioxidant defence system, and thereby causing oxidative damage in addition to activating pro-inflammatory pathways to cause cell death. Moderate ischemia and reperfusion may result in cell dysfunction, which may not lead to cell death due to activation of recovery systems to control ROS production and to ensure cell survival. However, prolonged and severe ischemia and reperfusion induce cell death by apoptosis, mitoptosis, necrosis, necroptosis, autophagy, mitophagy, mitochondrial permeability transition (MPT)-driven necrosis, ferroptosis, pyroptosis, cuproptosis and parthanoptosis. This review discusses cellular and molecular mechanisms of these various forms of cell death in the context of organ transplantation, and their inhibition, which holds clinical promise in the quest to prevent IRI and improve allograft quality and function for a long-term success of organ transplantation.
What problem does this paper attempt to address?
The paper aims to explore the cellular and molecular mechanisms of cell damage and cell death caused by Ischemia–Reperfusion Injury (IRI) during organ transplantation, and to propose methods to inhibit these mechanisms to prevent IRI and improve the function of transplanted organs.
### Main Research Content:
1. **Ischemic Phase**:
- Ischemia leads to a hypoxic state in tissues or organs, affecting cellular metabolism and bioenergy supply, causing cells to shift from aerobic to anaerobic metabolism due to mitochondrial electron transport chain dysfunction.
- This series of changes leads to an increase in intracellular Na+, H+, and Ca2+ concentrations, which in turn causes cellular edema.
2. **Reperfusion Phase**:
- During reperfusion, blood supply is restored to the ischemic tissue, leading to excessive generation of Reactive Oxygen Species (ROS), which exceeds the cell's antioxidant defense capacity, causing oxidative stress and lipid peroxidation.
- Simultaneously, pro-inflammatory pathways are activated, leading to cell death.
### Forms of Cell Death:
- **Necrosis**: Non-programmed cell death, mainly occurring in severe ischemia-reperfusion injury, leading to cell membrane rupture and inflammatory response.
- **Apoptosis**: Programmed cell death, usually occurring in milder ischemia-reperfusion injury.
- **Necroptosis**: Regulated form of necrosis, dependent on RIP1/3 proteins, triggering an inflammatory response.
- **Ferroptosis**: Iron-dependent regulated necrosis, characterized by lipid peroxidation accumulation, leading to loss of cell membrane integrity.
- **Other Forms of Cell Death**: Including autophagy, mitophagy, pyroptosis, cuproptosis, etc.
### Research Objectives:
- To explore various cell death mechanisms and their roles in organ transplantation.
- To propose new protective strategies to reduce the impact of IRI, such as using pharmacological inhibitors (e.g., PKC inhibitors, Src PTK inhibitors), gene therapy (e.g., knockout of specific genes), etc.
This review provides a detailed analysis of the various cell death mechanisms involved in ischemia-reperfusion injury and proposes multiple potential therapeutic strategies, aiming to provide a theoretical basis and technical support for the success of clinical organ transplantation.